Sight Sciences Expects 2026 Revenue of $82M to $88M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy SGHT?
The company said, "Sight Sciences expects its revenue for full year 2026 to range from $82 million to $88 million, representing growth of 6% to 14% compared to full year 2025. This revenue guidance includes Interventional Glaucoma segment revenue of $77 million to $81 million, representing growth of 2% to 7% and Interventional Dry Eye segment revenue of $5 million to $7 million, compared to $1.6 million in 2025. The Company expects adjusted operating expenses for full year 2026 to range from $93 million to $96 million, representing an increase of 6% to 9% compared to 2025. This increase is primarily due to targeted investments in both business segments, including expanded market access efforts and additional commercial resources to scale the reimbursed dry eye market and the pseudophakic standalone glaucoma opportunity."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SGHT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SGHT
Wall Street analysts forecast SGHT stock price to rise
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 3.700
Low
6.00
Averages
9.35
High
12.00
Current: 3.700
Low
6.00
Averages
9.35
High
12.00
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Sight Sciences Investor Claims
- Financial Performance Disclosure: On March 4, 2026, Sight Sciences reported its Q4 and full-year 2025 financial results, projecting total revenue for FY 2026 to be between $82 million and $88 million, including $5 million to $7 million from Interventional Dry Eye, highlighting both challenges and opportunities in the market.
- Stock Price Decline Impact: Following the financial disclosures, Sight Sciences' common stock experienced a significant decline, undermining investor confidence in the company's future prospects and potentially leading to investor losses, raising questions about the company's compliance with securities laws.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Sight Sciences' executives violated federal securities laws, suggesting that investors who suffered losses during this period may have legal recourse, indicating potential reputational risks for the company.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients, demonstrating its capability and influence in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
Sight Sciences Reports Q4 and Full Year 2025 Financial Results
- Improved Financial Performance: Sight Sciences reported a narrowed net loss of $4.16 million in Q4 2025, translating to $0.08 per share, down from $11.85 million or $0.24 per share in the previous year, indicating effective cost management and revenue growth strategies.
- Revenue Growth: The company achieved a 7% increase in total revenue to $20.39 million in Q4, primarily driven by an increase in ordering accounts and average selling prices, showcasing successful market demand and pricing strategies.
- Segment Performance: Revenue from the interventional dry eye and glaucoma segments rose to $0.72 million and $19.66 million respectively, highlighting sustained growth potential in these critical areas, particularly the significant rebound in the dry eye market.
- Future Outlook: For FY 2026, Sight Sciences anticipates total revenue between $82 million and $88 million, representing a growth of 6% to 14%, while glaucoma segment revenue is expected to range from $77 million to $81 million, reflecting confidence in future market demand.
See More
Sight Sciences Q4 2025 Earnings Call Insights
- Revenue Growth Highlight: Sight Sciences reported total revenue of $20.4 million in Q4 2025, reflecting a 7% year-over-year increase, with Interventional Glaucoma contributing $19.7 million and Interventional Dry Eye $0.7 million, indicating stable growth potential in both segments.
- Strong Gross Margins: The overall gross margin stood at 87%, with Interventional Glaucoma at 88% and Interventional Dry Eye improving to 68%, showcasing the company's ongoing efforts in cost control and operational efficiency.
- 2026 Revenue Guidance: The company projects 2026 revenue between $82 million and $88 million, representing a growth expectation of 6% to 14%, with targets for Interventional Glaucoma and Interventional Dry Eye set at $77 million to $81 million and $5 million to $7 million, respectively, reflecting confidence in future market opportunities.
- Robust Cash Flow Management: At the end of Q4 2025, the company had $92 million in cash and cash equivalents against $40 million in debt, and despite reporting a net loss of $4.2 million, management emphasized a disciplined cost structure to support future growth, aiming for cash flow breakeven.
See More
Sight Sciences Q4 Earnings Beat Expectations with Positive Revenue Guidance
- Earnings Highlights: Sight Sciences reported a Q4 GAAP EPS of -$0.08, beating expectations by $0.07, with revenue of $20.4 million reflecting a 7% year-over-year growth, indicating robust performance in the market.
- 2026 Revenue Guidance: The company anticipates full-year 2026 revenue to range from $82 million to $88 million, representing a growth of 6% to 14%, with the Interventional Dry Eye segment projected to generate $5 million to $7 million, significantly up from $1.6 million in 2025, showcasing strong growth potential.
- Operating Expense Increase: Sight Sciences expects adjusted operating expenses for 2026 to be between $93 million and $96 million, marking a 6% to 9% increase, primarily driven by targeted investments in market access and commercial resources to scale the reimbursed dry eye market and glaucoma opportunities.
- Market Expansion Strategy: The company aims to enhance its market share in the competitive medical device industry by increasing market access efforts and commercial resources, thereby positioning itself strategically for future growth in the dry eye and glaucoma segments.
See More
UBS Raises Sight Sciences Price Target to $12, Boosting Buy Rating
- Price Target Increase: UBS raised its price target for Sight Sciences from $7 to $12 while maintaining a Buy rating, reflecting increased market confidence in its Dry Eye Solution and potentially driving stock price appreciation.
- New Medicare Fee Schedule: Medicare Administrative Contractors Novitas and First Coast Service Option established a $1,140 fee for TearCare, marking a critical strategic milestone that significantly enhances market access for Sight Sciences, expected to accelerate TearCare utilization.
- Revenue Growth Potential: Analysts indicate that the new fee schedule provides a clearer pathway for revenue growth, with expectations of significant revenue increases by 2026, further enhancing the company's gross margins.
- Strategic Implications: The establishment of this fee schedule not only strengthens Sight Sciences' competitive position in the dry eye market but also lays the groundwork for future business expansion and market share growth.
See More
Sight Sciences (SGHT) Receives Upgrade to Buy: Key Information You Need to Know
Zacks Rank Upgrade: Sight Sciences, Inc. (SGHT) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential for stock price increase.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Sight Sciences has risen by 14.4% over the past three months, reflecting improved earnings outlook and business performance.
Correlation with Stock Movements: There is a strong correlation between earnings estimate revisions and near-term stock price movements, making the Zacks rating system a valuable tool for investors.
Top 20% Ranking: The upgrade places Sight Sciences in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for market-beating returns in the near future.
See More
Investigation into Sight Sciences Investor Claims
- Financial Performance Disclosure: On March 4, 2026, Sight Sciences reported its Q4 and full-year 2025 financial results, projecting total revenue for FY 2026 to be between $82 million and $88 million, including $5 million to $7 million from Interventional Dry Eye, highlighting both challenges and opportunities in the market.
- Stock Price Decline Impact: Following the financial disclosures, Sight Sciences' common stock experienced a significant decline, undermining investor confidence in the company's future prospects and potentially leading to investor losses, raising questions about the company's compliance with securities laws.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether Sight Sciences' executives violated federal securities laws, suggesting that investors who suffered losses during this period may have legal recourse, indicating potential reputational risks for the company.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients, demonstrating its capability and influence in protecting investor rights, which may encourage more affected investors to join the investigation.
See More
Sight Sciences Reports Q4 and Full Year 2025 Financial Results
- Improved Financial Performance: Sight Sciences reported a narrowed net loss of $4.16 million in Q4 2025, translating to $0.08 per share, down from $11.85 million or $0.24 per share in the previous year, indicating effective cost management and revenue growth strategies.
- Revenue Growth: The company achieved a 7% increase in total revenue to $20.39 million in Q4, primarily driven by an increase in ordering accounts and average selling prices, showcasing successful market demand and pricing strategies.
- Segment Performance: Revenue from the interventional dry eye and glaucoma segments rose to $0.72 million and $19.66 million respectively, highlighting sustained growth potential in these critical areas, particularly the significant rebound in the dry eye market.
- Future Outlook: For FY 2026, Sight Sciences anticipates total revenue between $82 million and $88 million, representing a growth of 6% to 14%, while glaucoma segment revenue is expected to range from $77 million to $81 million, reflecting confidence in future market demand.
See More
Sight Sciences Q4 2025 Earnings Call Insights
- Revenue Growth Highlight: Sight Sciences reported total revenue of $20.4 million in Q4 2025, reflecting a 7% year-over-year increase, with Interventional Glaucoma contributing $19.7 million and Interventional Dry Eye $0.7 million, indicating stable growth potential in both segments.
- Strong Gross Margins: The overall gross margin stood at 87%, with Interventional Glaucoma at 88% and Interventional Dry Eye improving to 68%, showcasing the company's ongoing efforts in cost control and operational efficiency.
- 2026 Revenue Guidance: The company projects 2026 revenue between $82 million and $88 million, representing a growth expectation of 6% to 14%, with targets for Interventional Glaucoma and Interventional Dry Eye set at $77 million to $81 million and $5 million to $7 million, respectively, reflecting confidence in future market opportunities.
- Robust Cash Flow Management: At the end of Q4 2025, the company had $92 million in cash and cash equivalents against $40 million in debt, and despite reporting a net loss of $4.2 million, management emphasized a disciplined cost structure to support future growth, aiming for cash flow breakeven.
See More
Sight Sciences Q4 Earnings Beat Expectations with Positive Revenue Guidance
- Earnings Highlights: Sight Sciences reported a Q4 GAAP EPS of -$0.08, beating expectations by $0.07, with revenue of $20.4 million reflecting a 7% year-over-year growth, indicating robust performance in the market.
- 2026 Revenue Guidance: The company anticipates full-year 2026 revenue to range from $82 million to $88 million, representing a growth of 6% to 14%, with the Interventional Dry Eye segment projected to generate $5 million to $7 million, significantly up from $1.6 million in 2025, showcasing strong growth potential.
- Operating Expense Increase: Sight Sciences expects adjusted operating expenses for 2026 to be between $93 million and $96 million, marking a 6% to 9% increase, primarily driven by targeted investments in market access and commercial resources to scale the reimbursed dry eye market and glaucoma opportunities.
- Market Expansion Strategy: The company aims to enhance its market share in the competitive medical device industry by increasing market access efforts and commercial resources, thereby positioning itself strategically for future growth in the dry eye and glaucoma segments.
See More
UBS Raises Sight Sciences Price Target to $12, Boosting Buy Rating
- Price Target Increase: UBS raised its price target for Sight Sciences from $7 to $12 while maintaining a Buy rating, reflecting increased market confidence in its Dry Eye Solution and potentially driving stock price appreciation.
- New Medicare Fee Schedule: Medicare Administrative Contractors Novitas and First Coast Service Option established a $1,140 fee for TearCare, marking a critical strategic milestone that significantly enhances market access for Sight Sciences, expected to accelerate TearCare utilization.
- Revenue Growth Potential: Analysts indicate that the new fee schedule provides a clearer pathway for revenue growth, with expectations of significant revenue increases by 2026, further enhancing the company's gross margins.
- Strategic Implications: The establishment of this fee schedule not only strengthens Sight Sciences' competitive position in the dry eye market but also lays the groundwork for future business expansion and market share growth.
See More
Sight Sciences (SGHT) Receives Upgrade to Buy: Key Information You Need to Know
Zacks Rank Upgrade: Sight Sciences, Inc. (SGHT) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential for stock price increase.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Sight Sciences has risen by 14.4% over the past three months, reflecting improved earnings outlook and business performance.
Correlation with Stock Movements: There is a strong correlation between earnings estimate revisions and near-term stock price movements, making the Zacks rating system a valuable tool for investors.
Top 20% Ranking: The upgrade places Sight Sciences in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for market-beating returns in the near future.
See More
